Italfarmaco and Medis ink distribution deal for DMD drug

Privately-held Italian pharma company Italfarmaco and Slovenia-based Medis Therapeutics have announced an exclusive distribution agreement for givinostat, the former company’s drug for the treatment of Duchenne muscular dystrophy (DMD).

Once approved by the European Commission and other relevant regulatory bodies, the partnership will facilitate patient access to givinostat across 17 countries in central and eastern Europe, including the Baltic states.

Givinostat, sold under the brand name Duvyzat, has already received regulatory approval in the USA and the UK, with an evaluation ongoing by the European Medicines Agency.